drugset / Trial / NCT00545337
Glulisine + Lantus in Type I Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR 1964) in subjects with type I diabetes mellitus
Timeline
- Start
- 2004-09
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin glulisine | Protein / enzyme biologic | — | Subcutaneous |